REG - Adv Medical Solutns. - Appointment of New Chair

Advanced Medical SolutionsAnnouncement

02/10/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231002:nRSB2667Oa&default-theme=true

RNS Number : 2667O  Advanced Medical Solutions Grp PLC  02 October 2023

            2 October 2023

 

            Advanced Medical Solutions Group plc

("AMS", the "Company" or the "Group")

 

            Appointment of Chair

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the
world-leading specialist in tissue-healing technologies, today announces the
appointment of Liz Shanahan, a current Non-Executive Director of AMS, as Chair
of the Board. Liz will succeed current Chair Peter Allen on 1 January 2024,
following a handover period. As previously communicated, Peter Allen is
stepping down after ten years with the Group.

 

Liz is a life sciences entrepreneur with extensive experience advising
leading global pharmaceutical and healthcare organisations on their
communications. She is currently a Non-Executive Director of AIM-listed
businesses Inspiration Healthcare Group plc (LON: IHC) and Celadon
Pharmaceuticals plc (LON: CEL) and was previously Non-Executive Director of
UDG Healthcare plc until its £2.8 billion takeover in August 2021. Between
2011 and 2014, she was Global Head of Healthcare & Lifesciences at the
NYSE-listed management consultancy, FTI Consulting Inc. Liz is a Trustee of
CW+, the charitable arm of Chelsea & Westminster Foundation Trust Hospital
in London and a member of the organisation's Innovations Advisory Board.
Alongside her Board appointments she is a business advisor and Executive
coach.

 

Upon appointment, Liz Shanahan will replace Peter Allen as Chair of the
Nomination Committee. A search is underway for the appointment of an
additional independent Non-Executive Director.

 

Chris Meredith, Chief Executive Officer of AMS, commented: "We look forward to
welcoming Liz as Chair in January. Her many years of life sciences experience
and significant contribution to AMS since joining as a Non-Executive Director
made her the ideal candidate to now lead the Board from 2024 onwards. Having
worked with Liz for the past years, I know the benefit, insight and strategic
guidance Liz will bring as we work closely together to execute the AMS growth
strategy.

 

"I want to express my personal thanks to Peter Allen. His commitment, passion
and advice have been invaluable over the past ten years and he has led the
Board through a significant period of growth. He will depart with our best
wishes for the future."

 

Liz Shanahan, commenting on her new role, said: "I am delighted to assume the
role of Chair of AMS during this pivotal time for the business, with entry
into new markets and product categories on the near horizon. It is clear to me
that the business has the ambition and capabilities to execute on the
attractive long-term growth opportunities in its markets. This is underpinned
by the team's drive and expertise. I look forward to working with Chris
Meredith, the Executive team and the rest of the Board, for the benefit of all
our stakeholders."

 

Peter Allen, departing Chair, commented: "I am proud of what AMS has achieved
during my time as Chair, particularly the integration of several acquisitions,
expansion of both the surgical and woundcare businesses and the benefit we
have brought for patients and payors through this. It has been a privilege to
spend ten enjoyable and successful years with this great business, but it is
now time to hand on the baton of Chair. I look forward to following AMS'
progress in the coming months and years."

 

 

 

- End -

 

For further information, please visit www.admedsol.com
(http://www.admedsol.com) or contact:

 

 Advanced Medical Solutions Group plc            Tel: +44 (0) 1606 545508
 Chris Meredith, Chief Executive Officer

 Eddie Johnson, Chief Financial Officer

 Michael King, Investor Relations

 ICR Consilium                                   Tel: +44 (0) 20 3709 5700
 Matthew Neal / Lucy Featherstone                AMS@consilium-comms.com

 Investec Bank PLC (NOMAD & Broker)              Tel: +44 (0) 20 7597 5970
 Gary Clarence / David Anderson

 HSBC Bank plc (Broker)                          Tel: 44 (0) 20 7991 8888
 Sam McLennan / Joe Weaving / Stephanie Cornish

 

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative
tissue-healing technology, focused on quality outcomes for patients and value
for payers. AMS has a wide range of surgical products including tissue
adhesives, sutures, haemostats, internal fixation devices and internal
sealants, which it markets under its brands LiquiBand(®), RESORBA(®),
LiquiBandFix8(®) and Seal-G(®). AMS also supplies wound care dressings such
as silver alginates, alginates and foams through its ActivHeal(®) brand as
well as under white label. Since 2019, the Group has made five acquisitions:
Sealantis, an Israeli developer of innovative internal sealants; Biomatlante,
a French developer and manufacturer of surgical biomaterials, Raleigh, a
leading UK coater and converter of woundcare and bio-diagnostics materials,
AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish
tissue adhesives specialist.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the
Czech Republic and Israel, are sold globally via a network of multinational or
regional partners and distributors, as well as via AMS's own direct sales
forces in the UK, Germany, the Czech Republic and Russia. The Group has
R&D innovation hubs in the UK, Ireland, Germany, France and Israel.
Established in 1991, the Group has more than 800 employees. For more
information, please see  www.admedsol.com (http://www.admedsol.com) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAFFFLIISLLIIV